Company intelligence / Profile preview

Osiris Trust

Columbia, Maryland, United States

Ownership: Private
Employees: ~360
Development stage: Other

Overview

Developed and commercialized regenerative medicine products including stem cell therapies like Prochymal (remestemcel-L, later Ryoncil) approved for pediatric GvHD in Canada (2012), Japan for Crohn's, EU for fistulas, and US FDA approval in Dec 2024; focused on wound care products post-stem cell asset sale.

Therapeutic areas: ImmunologyOtherEndocrinologyDermatologyGastroenterology
Modalities: Stem cell therapyMesenchymal stem cell therapy
Industry: Biotech

Partnerships

NovartisGenzymeMesoblast LimitedNuVasiveDepartment of Veteran AffairsDepartment of DefenseHowmedica Osteonics Corp.

Beyond the preview

Go deeper on Osiris Trust.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Osiris Trust.

Explore the full profile